Investor Materials
Investor Calendar
- 2025-11-28
Consolidated Report for Q3 2025
- 2025-09-30
Consolidated Report for H1 2025
- 2025-05-30
Consolidated Report for Q1 2025
- 2025-04-30
Separate and Consolidated Full-Year Report for 2024
Frequently Asked Questions (FAQ)
What does Scope Fluidics do, and what is its business model?
Scope Fluidics S.A. is a life science company engaged in developing cutting-edge technologies for the medical diagnostics and healthcare markets. Scope Fluidics operates under a Venture Studio model – identifying worldwide challenges and market opportunities, and transforming them into concepts for breakthrough products. Its focus lies in healthcare, where it applies a rigorous process for selecting and developing projects with strong commercial prospects globally. The Company’s strategy is to create value by bringing projects to maturity and executing strategic transactions, including sales to international medtech operators.
How much did you get for selling the SPV Curiosity Diagnostics (PCR|ONE project) to Bio-Rad?
The Company has demonstrated its global potential by completing the largest transaction to date in the Polish life science sector: the sale of the PCR|ONE system to US-based Bio-Rad Laboratories for a total of USD 130 million. This landmark deal strengthens our credibility with other global partners and paves the way for future M&A transactions. The Company’s strategy is to create value by bringing projects to maturity and executing strategic transactions, including sales to international medtech operators.
What are Scope Fluidics’ key current projects?
Its most advanced project currently under development is BACTEROMIC, a rapid, automated Antibiotic Susceptibility Testing (AST) system, which provides precise, actionable insights to guide the selection of effective antibiotic therapies, combining high performance with ease of use. Results from the Early Access Programme (EAP) confirm both the system’s readiness for broader market launch and its significant competitive advantages. In addition, the Scope Fluidics Group is advancing two early-stage projects: 1) EDOCERA – a system designed for the rapid diagnosis of stroke, enabling immediate medical intervention, and 2) HYBOLIC – a system intended for the early detection of metabolic syndrome risks, including insulin resistance and type 2 diabetes, by monitoring key biomarkers such as insulin and glucose levels.
What is the expected timeline for an M&A transaction involving the BACTEROMIC project?
At this stage, we are not committing to any specific timeline for a potential M&A transaction involving BACTEROMIC. Our strategy outlines a goal to complete two strategic transactions by the end of 2028. While prevailing market sentiment in the M&A sector remains challenging, we are taking active steps to position BACTEROMIC for success, just as we did with PCR|ONE. The Management Board remains confident in achieving a successful transaction.
Is EDOCERA ahead of the HYBOLIC project in terms of development?
Both projects are advancing more or less in parallel.
Given the early stages of EDOCERA and HYBOLIC, is it realistic to complete two strategic transactions by the end of 2028?
Currently, we see no reason to believe otherwise.
How do you assess the activities of Scope Discovery, the unit responsible for developing new concepts, and what are the key aspects of your project selection process?
We are very pleased with the performance of Scope Discovery and with the rigour of our process for creating and evaluating new projects. Each project goes through a 24-step methodology, originally developed by MIT and adapted to meet our specific needs. This proven approach has delivered strong results for our pipeline. We select projects that meet all three of the following criteria: 1) market attractiveness – a clear commercial opportunity, 2) ambitious technological challenge – creating a natural barrier to competition, 3) ability to address real-world market needs – which is our primary selection factor.